18:00 | 23.10.2008
DGAP-News: MIV Therapeutics Featured on Front Page of Medical Device Daily
MIV Therapeutics Inc. / Miscellaneous
23.10.2008
Release of a Corporate News, transmitted by DGAP – a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
—————————————————————————
October 22, 2008, Edition Includes Article Highlighting MIV’s
Peer-Reviewed Journal Article Publishing VESTASYNC I Trial Results
ATLANTA, GA – October 23, 2008 – MIVMIV Therapeutics, Inc. (OTC/BB: MIVI)
(Frankfurt: MIVN Therapeutics, Inc. (OTC/BB: MIVI) (Frankfurt: MIVN,
wwwwww.mivtherapeutics.com.mivtherapeutics.com), a leading developer of
next-generation coatings and advanced drug delivery systems for
cardiovascular stents and other implantable medical devices, was featured
on the front page of MedMedical Device Dailyical Device Daily’s October 22,
2008, edition.
The article by Amanda Pedersen titled, ‘JACCC publishes MIV’s VESTASYNC
I trial results,’ highlights the Journal of the American College of
Cardiology’srnal of the American College of Cardiology’s (JACC)
publication of preliminary results from its VESTASYNC I first human trial.
The peer-reviewed article titled, ‘Preliminary Results of the
Hydroxyapatite Non-Polymer-Based Sirolimus-Eluting Stent for the Treatment
of Single De Novo Coronary Lesions – A First-In-Human Analysis of a Third
Generation Drug-Eluting Stent (DES) System,’ appeared in the October 21st
edition of JACC and is available online at
http://interventions.onlinejacc.org/.
The extended version can be requested via info@vastani.como@vastani.com.
The Medical Device Daily ical Device Daily piece explains, ‘DES makers
have been in a race to address the safety issues surrounding DES ever since
it became associated with a higher rate of thrombosis, or blood clotting.’
In the article, Dr. Mark Landy, MIV President and Chief Executive Officer,
said, ‘From our perspective the one way to try and solve these issues is to
eliminate the polymer and then once and for all we know if it’s a drug
issue or a polymer issue.’
The article goes on to explain that in the VESTASYNC I trial, the VESTAsync
DES was successfully implanted in all cases without complications. ‘At four
months, in-stent late lumen loss was 0.30 + 0.25 mm and percent of stent
obstruction was 2.8 + 2.2%. The VESTAsync DES late loss of 0.30 mm situates
this new device among the highest-efficacy DES, with the advantage of a
polymer-free system using less than 50% drug than first-generation
equivalents.’
Dr. Landy continues in the article, ‘VESTAsync stent’s benefits fall into
three broad categories: biocompatibility, accelerated healing and a more
efficient drug-delivery system.’ In addition the company believes the
VESTAsync will significantly ‘reduce the length of time the patient
requires anti-platelet therapy after a procedure to 3 months.’ The current
anti-platelet standard is a minimum duration of one year and in many cases
is life-long therapy.
MIV is currently enrolling patients in the VESTASYNC II trial, a
120-patient randomized controlled study designed to demonstrate the safety
and efficacy of the VESTAsync stent in a larger group of patients.
About MIV Therapeutics
MIV Therapeutics is developing a next-generation line of advanced
biocompatible coatings for passive and drug-eluting applications on
cardiovascular stents, as well as for a broad range of other implantable
medical devices. The Company’s ultra-thin coating formulation is designed
to protect surrounding tissue from potentially harmful interactions with
bare metallic stents. This coating platform is derived from hydroxyapatite
(HAp), an organic material that has demonstrated excellent in vivo safety
and biocompatibility. Hydroxyapatite is a porous material that makes up the
bone mineral and matrix of teeth, and is widely used today as a bone
substitute material and for coatings on implantable fixation devices in
orthopedic, dental and other applications. The Company’s novel polymer-free
drug-eluting technologies based on HAp could also provide an attractive
alternative to current polymer-based drug-eluting coatings on the stent
market, which have been associated with undesirable effects. The Company’s
drug-eluting coatings are additionally designed to suit a broad range of
implantable medical devices that could benefit from highly customizable
drug release profiles. MIV Therapeutics has a Collaborative Research
Agreement with the University of British Columbia and has received a
government grant for its research program on the ‘Development of Novel Drug
Eluting Composite Coatings for Cardiovascular Stents,’ under the National
Research Council-Industrial Research Assistance Program. Under this
sponsorship, the Company is expected to complete its drug-eluting research
and development program and to reach product commercialization. MIV’s
intellectual property portfolio includes patents held by the University of
British Columbia and exclusively licensed to MIV. Key patent applications
filed simultaneously in various countries around the world further protect
the commercial exclusivity of MIV’s inventions in the global marketplace.
For more information, please visit www.mivtherapeutics.com.
Forward-Looking Statements
Except for the historical information contained herein, the matters
discussed in this press release are forward-looking statements. All
statements that discuss expectations and projections with respect to future
matters including, without limitation, statements relating to the safety
and efficacy of the Company’s product and the ability of the Company’s
product to rejuvenate the stent market are forward-looking statements. Such
statements are indicated by words or phrases such as ‘proposed,’
‘expected,’ ‘believe,’ ‘will,’ ‘breakthrough,’ ’significant,’ ‘indicated,’
‘feel,’ ‘revolutionary,’ ’should,’ ‘ideal,’ ‘extremely’ and ‘excited.’
These statements are made under ‘Safe Harbor’ provisions of the Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those described in forward-looking statements and are
subject to risks and uncertainties including, without limitation, market
acceptance of the Company’s product, the ability of the Company to raise
sufficient funding and to continue to develop its various business
interests as presently contemplated, and other factors identified in the
Company’s filings with the Securities and Exchange Commission including,
without limitation, the Company’s annual report on Form 10-K for the year
ended May 31, 2007 and Forms 10-Q. The Company expressly disclaims any
obligation to update publicly or otherwise revise these statements, whether
as a result of new information, future events or otherwise, except to the
extent required by law.
Investor Relations:
Anthony L. Huston
+1 604-301-9545 ext. 14
Vice President, Business Development & Investor Relations
ahuston@mivtherapeutics.com
investor@mivtherapeutics.com
The Investor Relations Group
Rachel Colgate / Michael Crawford
+1 212-825-3210
Media Relations:
Laura Colontrelle / Janet Vasquez
+1 212-825-3210
23.10.2008 Financial News transmitted by DGAP
—————————————————————————
|
